Related Experiment Video
Updated: Jun 13, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
A Favorable Modifiable Risk Factor Profile Mitigates Polygenic Risk for Alzheimer's Disease and Related Dementia
Background:
A recent Lancet Commission estimated that up to 45% of Alzheimer's Disease and Related Dementias (ADRD) cases could be prevented by addressing modifiable lifestyle risk factors. Meanwhile, genome-wide association studies (GWAS) have shown that common genetic variants also account for substantial ADRD risk. Whether a favorable lifestyle can offset risk in genetically predisposed individuals remains unclear.
Methods:
We conducted a retrospective cohort study of 105,886 participants from the All of Us Research Program enrolled between 2018-2023. Participants were over age 49, assigned male or female at birth, of European ancestry, and without ADRD at baseline. ADRD diagnoses were identified via electronic health records (EHR). Fourteen potentially modifiable risk factors for ADRD were assessed using surveys, EHR records, and wearable data. Genetic risk was quantified as a polygenic risk score (PRS) based on 81 independent GWAS loci and APOE ε4 genotype.
Results:
Overall, 967 incident ADRD events occurred over a median follow-up of 3.7 years. Ten out of 13 modifiable risk factors were significantly associated with ADRD. When grouped into risk factor profiles, intermediate and unfavorable modifiable risk factor scores were associated with substantially higher ADRD risk (HR 3.07, 95% CI 2.47-3.83; HR 8.01, 95% CI 6.39- 10.05, respectively) compared to a favorable lifestyle; APOE ε4 dosage and polygenic risk score were also independently associated with ADRD risk. Among individuals in the highest polygenic risk group, a favorable lifestyle reduced ADRD risk from HR 18.63 (95% CI 10.25-33.86) to 1.90 (95% CI 0.94-3.81), whereas APOE ε4 homozygotes remained at elevated risk even with a favorable lifestyle (HR 6.52, 95% CI 2.97-14.33).
Conclusions:
Our data suggest ADRD risk is driven more by modifiable risk factors and APOE genotype than polygenic risk score. Future genomic-informed risk assessments for ADRD should calibrate their findings to accurately identify high-risk individuals.
More Related Videos
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Pharmacogenomics: Identification of New Drug Targets
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Atherosclerosis III: Management

